Effect of Standard Heparin and a Low Molecular Weight Heparin on Thrombolytic and Fibrinolytic Activity of Single-Chain Urokinase Plasminogen Activator In Vitro

Summary

The effect of unfractioned heparin (UH) and low molecular weight heparin (LMWH) (Kabi 2165 - Fragmin^®) on in vitro scu-PA thrombolytic and fibrinogenolytic activity was investigated. Thrombolytic activity was evaluated by following lysis of radiolabeled plasma clot immersed in plasma in presence of scu-PA alone or with either form of heparin. A 200 IU/ml scu-PA concentration produced clot lysis within 7 hr. UH or LMWH led to a slightly faster clot lysis which was statistically significant only at the 2nd and 3rd hour. No significant difference could be evidenced between UH and LMWH effect. During clot lysis, plasmin, generated within the clot led to a gradual transformation of scu-PA to tcu-PA, specially after a 4-hr incubation. Appearance of tcu-PA activity in the plasma surrounding the clot was significantly inhibited by either form of heparin. This finding contrasts with results observed in purified systems and suggests the presence of heparin-dependent plasma factor(s) inhibiting tcu-PA formation or its activity. Possible candidates might be anti-thrombin III and PAI-3.

No fibrinogen breakdown was observed when plasma was incubated for 7 hr at 37° C in presence of scu-PA alone (200 IU/ ml) or with either form of heparin. However, in presence of a plasma clot, an important fibrinogen breakdown was observed during clot lysis reflecting the action of plasmin and/or tcu-PA generated within the clot, in the surrounding plasma. Fibrinogenolysis was less pronounced in the presence of both heparin preparations possibly as a consequence of the reduction in the tcu-PA level. These results underline the importance of plasma factors in the interaction of heparin with plasminogen activators such as scu-PA.

Keywords

scu-PA - Standard heparin - Low molecular weight heparin

• References

• 1 Markwardt F, Klöcking HP. Heparin-induced release of plasminogen activator. Haemostasis 1977; 6: 370-374
• 2 Andrade-Gordon P, Strickland S. Interaction of heparin with plasminogen activators and plasminogen: effects on the activation of plasminogen. Biochemistry 1986; 25: 4033-4040
• 3 Paques EP, Stohr HA, Heimburger N. Study on the mechanism of action of heparin and related substances on the fibrinolytic system: relationship between plasminogen activators and heparin. Thromb Res 1986; 42: 797-807
• 4 Lijnen HR, Collen D. Stimulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinasetype plasminogen activators. Thromb Res 1986; 43: 687-690
• 5 Dosne AM, Bendetowicz AV, Kher A, Samama M. Marked potentiation of the plasminogenolytic activity of pro-urokinase by unfractioned heparin and a low molecular weight heparin. Thromb Res 1988; 51: 627-630
• 6 Klauser RJ. Induction of fibrinolysis by polyanions in human plasma. Thromb Haemostas 1988; 60: 324-327
• 7 Fry ET A, Sobel BE. Lack of interference by heparin with thrombolysis or binding of tissue-type plasminogen activator to thrombi. Blood 1988; 71: 1347-1352
• 8 Cercek B, Lew AS, Hod H, Yano J, Reddy NK N, Ganz W. Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. Circulation 1986; 74: 583-587
• 9 Stassen JM, Juhan-Vague I, Alessi MC, Decock F, Collen D. Potentiation by heparin fragments of thrombolysis induced with human t-PA or human single-chain urokinase-type plasminogen activator. Thromb Haemostas 1987; 58: 947-950
• 10 Doutremepuich C, Toulemonde F, Doutremepuich F, de Séze O, Bayrou B, Pereira F. The tPA-like activity induced by heparin and a heparin fragment binds on experimental thrombus. Thromb Res 1988; 50: 335-338
• 11 Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh NA, Gaffney PJ. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-224
• 12 Gulba DC, Fisher K, Reil GH, Daniel WG, Lichtlen PR. Potentiation of the thrombolytic efficacy of single-chain urokinase (pro-urokinase) by heparin. Thromb Haemostas 1988; 60: 350-351
• 13 Agnelli G, Borin J, Cosmi B, Levi M, Cate JW T. Effects of standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis. Thromb Haemostas 1988; 60: 311-313
• 14 Grimaudo V, Omri A, Kruithof EK O, Hauert J, Bachmann F. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination. Thromb Haemostas 1988; 59: 388-391
• 15 Fears R. Kinetic studies on the effect of heparin and fibrin on plasminogen activators. Biochem J 1988; 249: 77-81
• 16 Gurewich V. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator. J Am Coll Cardiol 1987; 10: 16B-21B
• 17 Kasper W, Meinertz T, Hohnloser S, Engler H, Hasler C, Rossler W, Wolf H, Welzel D, Just H, Gurewich V. Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase. Klin Wochenschr 1988; 66 suppl XII 109-114
• 18 Kindress G, Williamson FB. Modification by anionic polysaccharide of the antithrombin III inhibition of plasmin. Biochem Soc Trans 1980; 8: 652-653
• 19 Murano G, Aronson D, Williams L, Brown L. Inhibition of high and low molecular weight urokinase in plasma. Blood 1980; 55: 430-436
• 20 Stump DC, Thienpont M, Collen D. Purification and characterization of a novel inhibitor of urokinase from human urine. Quantification and preliminary characterization in plasma. J Biol Chem 1986; 261: 12759-12766
• 21 Stief TW, Radtke KP, Heimburger N. Inhibition of urokinase by protein C-inhibitor (PCI). Evidence for identity of PCI and plasminogen activator 3. Biol Chem Hoppe-Seyler 1987; 368: 1427-1433
• 22 Zamarron C, Lijnen HR, van Hoef B, Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinase. I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology. Thromb Haemostas 1984; 52: 19-23
• 23 Gurewich V, Pannell R, Louie S, Kelley P, Suddith RL, Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest 1984; 73: 1731-1739
• 24 Rijken DC, Binnema DJ, Los P. Specific fibrinolytic properties of different molecular forms of pro-urokinase from a monkey kidney cell culture. Thromb Res 1986; 42: 761-768
• 25 Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215-1223
• 26 Hanbücken FW, Schneider J, Giinzler WA, Friderichs E, Giertz H, Flohe L. Selective fibrinolytic activity of recombinant non glycosylated human pro-urokinase (single-chain urokinase-type plasminogen activator from Bacteria). Arzneim-Forsch/Drug Res 1987; 37: 1-5
• 27 Samama M, Nguyen G, Desnoyers P, Lourenso DM, Fretault J, Horellou MH, Conrad J, Szwarcer E, Verdy E, Vahanian A. Comparison of thrombolytic fibrinolytic and fibrinogenolytic properties of tissue plasminogen activator, streptokinase single-chain urokinase, high molecular weight and low molecular weight urokinase in plasma in vitro. Fundam Clin Pharmacol 1988; 2: 509-524